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Abstract: Brown seaweeds contain many bioactive compounds, including polyphenols,
polysaccharides, fucosterol, and fucoxantin. These compounds have several biological activities,
including anti-inflammatory, hepatoprotective, anti-tumor, anti-hypertensive, and anti-diabetic
activity, although in most cases their mechanisms of action are not understood. In this study,
extracts generated from five brown algae (Fucus dichitus, Fucus vesiculosus (Linnaeus), Cytoseira
tamariscofolia, Cytoseira nodacaulis, Alaria esculenta) were tested for their ability to activate SIRT6
resulting in H3K9 deacetylation. Three of the five macroalgal extracts caused a significant increase of
H3K9 deacetylation, and the effect was most pronounced for F. dichitus. The compound responsible
for this in vitro activity was identified by mass spectrometry as fucoidan.
Keywords: sirtuin activators; fucoidan; brown seaweed
1. Introduction
SIRT6 is an NAD+-dependent histone deacetylase (HDACs EC 3.5.1.98) that functions as a
regulator of many cellular processes, is evolutionarily conserved, and exists in a variety of organisms
from eukaryotes to humans [1,2]. SIRT6 controls healthy ageing by regulating genomic stability,
oxidative stress, and glucose metabolism, and it is considered a promising target for age-associated
diseases such as chronic inflammation, diseases associated with metabolic syndrome, obesity, and
insulin resistant type-2 diabetes [3–8]. In a recent study, it was demonstrated that SIRT6 inhibition could
improve glycemia in a mouse model of type 2 diabetes [9]. Also, it was shown that SIRT6-deficient
mice have a premature aging phenotype with a shortened lifespan, while the overexpression of SIRT6
prolongs the lifespan in male mice and prevents diet-induced obesity [4,10]. SIRT6 activity affects
the development of several cancer subtypes, but it is still unclear whether it is a tumor suppressor or
promoter, or both [2,11].
Some compounds that enhance SIRT6 activity have been identified, including fatty acids and
endogenous fatty acid ethanolamides [12,13]. Phenolic compounds, such as quercetin and luteolin,
also enhance SIRT6 deacetylation activity, albeit at very high concentrations [13].
Brown macroalgal species [14–16], specifically Fucaceae and Cystoseira, are rich in molecules that
exert a large range of biological activities including phenolic compounds such as phlorotannins, and
polysaccharides, such as laminarans and fucoidans. Phlorotannins protect cells against Ultraviolet
Mar. Drugs 2017, 15, 190; doi:10.3390/md15060190 www.mdpi.com/journal/marinedrugs
Mar. Drugs 2017, 15, 190 2 of 12
(UV)-B-induced DNA modifications by inducing the nucleotide excision repair (NER) pathway of
DNA repair [17]. Fucoidans are a complex heterogeneous group of sulfated polysaccharides composed
of L-fucose and sulphate ester groups with minor amounts of monosaccharides that have robust
anti-inflammatory and anti-proliferative effects [18,19].
Considering the elicited physiological actions of brown seaweeds and their overlap with the
reported bioactivity of SIRT6, the aim of this work was to screen brown seaweed species for novel
SIRT6 modulators as potential candidates that can be used in the prevention of age-associated diseases
and metabolic syndrome associated disorders, including cancer, obesity, and insulin-resistant diabetes.
We used an accelerated solvent extraction (ASE®) method with acetone:water (70:30 v/v) [15,19]
as an extraction solvent to generate phlorotannin- and fucoidan-rich extracts from five species of
brown macroalgae, namely Fucus distichus, Fucus vesiculous, Cytoseira tamariscofolia, Cytoseira nodacaulis,
and Alaria esculenta. The generated extracts were tested for their ability to deacetylate H3K9, a
proxy measure of SIRT6 activity. Three of the five macroalgal extracts significantly enhanced SIRT6
activity, and the effect was most pronounced for F. distichus. Herein, we identify fucoidan as the
compound responsible for SIRT6 activation from F. distichus extract using liquid chromatography and
mass spectrometry.
2. Results
2.1. Screening of Brown Algae
In this study, we used a previously developed HPLC deacetylation assay that estimates SIRT6
activity by measuring changes in the level of deacetylated peptide H3K9, over the substrate
(H3K9Ac) [13,20], to determine SIRT6 activity in complex matrices. Five species of brown algae
were tested for SIRT6 modulating activity at two concentrations (Figure 1). Of these, the A. esculenta
ASE® extract had no activity, while C. nodacaulis displayed SIRT6 stimulating activity, with a ~five-fold
increase at 1 mg/mL compared to control. The ASE® extracts from F. distichus, F. vesiculosus (Linnaeus),
and C. tamariscofolia all displayed an approximate ~35-fold increase in SIRT6 activity when assayed
at a concentration of 1 mg/mL. While the stimulation of SIRT6 activity was dose-dependent for all
species tested, F. distichus displayed the strongest activity at 0.5 mg/mL with a ~10-fold increase. As a
result, F. distichus was studied further.
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Figure 1. SIRT6 deacetylation activity in the presence of five species of brown algae extracts. The change
of SIRT6 deacetylation in the presence of 0.5 mg/mL (grey) and 1.0 mg/mL (light grey) extracts is
compared to controls with 500 µM NAD+ and 40 µM H3K9Ac with 30 min of incubation time. The data
are presented as means ± SD, n = 3.
2.2. Separation of F. distichus
F. distichus was separated into eight sub-fractions (F1–F8) using an XDB-C18 column
(Zorbax Eclipse) guided by the SIRT6 H3K9Ac deacetylation HPLC-based assay (Figure 2). Of the
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eight sub-fractions, moderate activity was observed for F3–F6, and F8 (Figure 3), with a ~3-fold
increase in SIRT6 activity. Interestingly, F1 and F7 were the most active, with a ~70-fold and ~40-fold
increase, respectively, in SIRT6 activity, at 1 mg/mL. Due to the increased activity observed in F1,
the HPLC method was scaled up for the collection of more active fractions with semi-preparative
HPLC-PDA (Supplementary Figure S1) using an Eclipse XDB-C8 (9.4 mm × 250 mm, 5 µm). Five
different fractions (F1–F5) were collected and the resulting F1 fraction was further purified using a
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Figure 3. SIRT6 deacetylation activity (fold activity relative to control) of fractions (F1–F8) from F. distichus
in the presence of 0.5 mg/mL (grey) and 1.0 mg/mL (light grey) fractions (F1–F8) with 500 µM NAD+
and 40 µM H3K9Ac with 30 min of incubation time. The data are presented as means ± SD, n = 3.
2.3. Identification of Fucoidan
The resulting sub-fraction was characterized by mass spectrometry (Figure 4), and identified
as fucoidan, a sulfated polysaccharide present in brown algae, by comparison to the reported
mass spectra of isolated fucoidan from Sargassum genus algae [21,22]. The seaweed fucoidans
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are heterogenic mixtures of structurally related polysaccharides consisting of carbohydrate units
(L-fucopyranose and non-fucose ones) and non-carbohydrate substituents (mainly sulfate and acetyl
groups). The precise determination of their structures with the exact location of structural elements
is complex. The polysaccharide backbones of fucoidans are organized in repeating (1→3)-linked
or alternatively (1→3)- and (1→4)-linked α-L-fucopyranose residues [23,24]. The backbone of the
fucoidan from F. distichus is built up mainly of the repeating A units (Figure 5), whereas fucoidans
from F. vesiculosus are formed mainly of B units [23–25].
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Figure 5. Reported structural elements for fucoidan isolated from the brown seaweeds (A) F. distichus,
(B) F. vesiculosus. Modified from [24,25].
While the employed extraction process aimed to isolate phlorotannins, the presence of fucoidan
in the extracts is not unexpected, as it has been previously reported that between 0.26% and 7.0% dry
weight of the algal biomass of F. distichus consists of fucoidan [24]. Furthermore, Béress [26] previously
reported the extractio of both polyp enol and polymers including fucoidan usi g water-based
solvent systems. It is difficult to separate polyphenols and carbohydrates based on the differential
solubility of these algal components. Pantankar previously reported that fucoidan is soluble in
acetone:water [27], and this is also a well-known extraction solvent for phlorotannins. A dose-response
curve of a sub-fraction of F1 was carried out, and the results demonstrated a significant increase
in SIRT6 activation with a ~140-fold increase observed at a 100 µg/mL concentration (Figure 6A).
However, due to the limitations in the amount of F. distichus available, we were unable to obtain a full
dose-response curve for the sub-fraction of F1. Fucoidan (>95% pure) was purchased (isolated from
F. vesiculosus) and a full dose-response curve was carried out. The dose-response curve obtained was
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Figure 6. (A) Dose-response curve of the extract sub-fraction of F1 ( ) in the presence of 500 µM NAD+
and 40 µM H3K9Ac with 30 min of incubation time. The data are presented as means ± SD, n = 3;
(B) Dose-response curve of fucoidan () on SIRT6 deacetylation ctivity i the presence of 500 µM NAD+
and 40 µM H3K9Ac with 30 min of incubation time. The data are presented as means ± SD, n = 3.
2.4. Western Blot Analysis
The in vitro deacetylation activity was also determined by Western blot analysis, where 1 to
16 µg/mL of fucoidan was incubated with the core histones and the remaining levels of histone H3
acetylated on lysine 9 were determined. Using this technique, it was found that fucoidan activated
SIRT6 deacetylation activity in a dose-dep ndent manner (Figure 7). Both methods d monstrate
that fucoidan is an activator of SIRT6. Interestingly, it was demonstrated that higher concentrations
of fucoidan (>16 µg/mL in the Western blot analysis method) resulted in the reduced activation of
SIRT6 activity (data not shown). A similar observation was made in the HPLC-based assay at higher
concentrations as well, indicating that fucoidan may have a dual role in SIRT6, similar to what was
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Figure 7. Western blot method for the in vitro SIRT6 deacetylation assay. Serially diluted concentrations
of a SIRT6 stimulator (1–16 µg/mL) were incubated for 30 min at 37 ◦C in the presence of 1 µg/well
of a purified recombinant GST-SIRT6 protein, 2 µg purified whole chicken core histones with 500 µM
NAD+ in 25 mM Tris-HCl, pH 8.0. (A) Acetylation level was detected with anti-H3K9Ac antibody
and normalized to total H3 histone. Values indicate final fucoidan concentration in µg/mL. Molecular
weight markers in kDa. (B) Quantification of H3K9 deacetylation. Values represent the averages of
three experiments; error bars indicate standard deviation.
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2.5. Selectivity for SIRT6
In order to determine whether fucoidan was selective for SIRT6, in vitro enzymatic assays were
carried out against SIRT1, SIRT2, and SIRT3. Neither 10 µg/mL nor 100 µg/mL of fucoidan resulted in
any change in the deacetylation activity of SIRT1 or SIRT3. There was a 20% reduction in SIRT2 activity
at 100 µg/mL (Table 1). These results suggest that fucoidan activation of sirtuins is specific to SIRT6.
Table 1. Fucoidan against SIRT1-SIRT3 deacetylation activities. The data are presented as means ± SD,
n = 3.
Fucoidan (µg/mL) Fold Increase in Activity ± SD
SIRT1 SIRT2 SIRT3
10 0.96 ± 0.04 0.87 ± 0.06 0.99 ± 0.01
100 0.94 ± 0.02 0.82 ± 0.02 0.98 ± 0.02
3. Discussion
From five species of brown algae tested against SIRT6 modulating activity, F. distichus displayed the
most robust increase of SIRT6 deacetylation activity. As a result, the active component from F. distichus
was identified using a guided SIRT6 H3K9Ac deacetylation HPLC-based assay as fucoidan. Due to
the limitations of the starting material, commercially available fucoidan (isolated from F. vesiculosus)
was purchased and tested for SIRT6 activity. A significant increase in deacetylation activity was
observed in a dose-dependent manner using the HPLC-guided deacetylation-based assay as well
Western blot analysis. The commercial fucoidan, from F. vesiculosus, has been reported to contain
fucose (>50%), galactose (6%), glucose (20%), mannose, xylose (15%), uronic acid, glucosamine,
and sulfate [28]. None of these monosaccharides introduced any SIRT6 activity at a concentration
up to 300 µM (data not shown), indicating that the activity is most likely due to the sulfated fucose.
Percival and Ross reported that fucoidan from F. vesiculosus contained 31.7% sulfation [29], while the
sulfate content of commercial fucoidan from F. vesiculosus was estimated to be 31.2% [30,31]. Previous
studies revealed that the degree of sulfation significantly influences the level of anti-angiogenic activity
of fucoidans in human umbilical vein endothelial cells. For example, oversulfated fucoidan from
F. vesiculosus with sulfate contents at 52.4% were significantly stronger at inhibiting angiogenesis
than natural fucoidan from F. vesiculosus with sulfate contents of 31.2% [30,32]. The modulation
of sirtuin activity by negatively charged sulfated polysaccharides, while novel, is not completely
unexpected. For example, Tong et al. [33] reported the activation of SIRT7 deacetylation activity
with negatively charged DNA. In addition, heparin and heparan sulfate proteoglycans have been
reported to be potent inhibitors of HAT (Histone acetyltransferases) activity [34]. Further, fucoidan
has been indicated to play a role in apoptosis [28,35,36]. In one study, it induced the cleavage of PARP
(poly ADP ribose polymerase) to the 89 kDa polypeptide, suggesting that caspases were involved in
the fucoidan-mediated apoptosis [37]. Furthermore, in a study in rabbits investigated fucoidan injected
intramuscular (i.m.)-induced apoptosis in isolated lymphoma cell lines in vitro [28]. Similarly, SIRT6
overexpression has been demonstrated to induce apoptosis in cancer cells and not in normal cells [8].
In cancer cells, the activity was mediated via the activation of both p53 and p73 signaling cascades.
Min et al. [38] reported that the treatment of HepG2 cells with fucoidan (250 and 500 µg/mL) increased
the upregulation of p53 and p14, which are involved in the regulation of apoptosis, by up to two- and
two and half-fold, respectively, thus inhibiting the viability of HepG2 cells. Zhang et al. (2014) [39]
reported a direct interaction between SIRT6 and p53, and the activation of SIRT6 expression by
intact p53, which in turn leads to an elevated association of SIRT6 with FoxO1 and the subsequent
inhibition of gluconeogenesis. In addition to anti-cancer properties, fucoidans have revealed numerous
other health-promoting effects, including anti-oxidative and anti-inflammatory effects. In addition to
observations with SIRT6, it was demonstrated in a mouse model that low molecular weight fucoidan
inhibited oxidative stress and mitochondrial dysfunction through the upregulation of the expression
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of SIRT3 after traumatic brain injury [40]. While these studies suggest that fucoidan could also be
activating other sirtuins, the results of this study demonstrate that fucoidan, isolated from F. distichus
and F. vesiculosus, is a strong stimulator of SIRT6. To our knowledge, this is the first report to identify a
polysaccharide which stimulates SIRT6 deacetylation activity.
4. Materials and Methods
4.1. Materials
Acetylated histone H3 (K9) peptide (residues 1-21) (H3K9Ac) was purchased from AnaSpec
Incorporation (Fremont, CA, USA). Nicotinamide adenine dinucleotide (NAD), formic acid, fucoidan
from F. vesiculosus (F5631), and anti-rabbit HRP-conjugated secondary antibody (A0545) were ordered
from Sigma Aldrich (St. Louis, MO, USA). Core histones proteins (13-107) and rabbit anti-acetyl H3K9
antibody (06-942) were ordered from Merck, EMD Millpore (Temecula, CA, USA). Rabbit anti-histone
H3 antibody (9715S) was purchased from Cell Signaling Technology (Danvers, MA, USA). Novex™
WedgeWell™ 10–20% Tris-Glycine Mini Gels (12-well) (XP10202BOX) and Novex® Tris-Glycine SDS
Running Buffer (10×) (LC2675) were ordered from ThermoFisher Scientifics (Waltham, MA, USA).
Expression and Purification of GST-Tagged SIRT6 Protein. The human SIRT6 expression
vector hSIRT6-pGEX-6P3 was kindly provided by Prof. Katrin Chua (Stanford, CA, USA).
The recombinant GST (Glutathione S-transferases)-tagged SIRT6 was produced by fermentation
in Escherichia coli BL21 (DE3)-pRARE. The production was done at +16 ◦C with 0.1 mM IPTG
(Isopropyl β-D-1-thiogalactopyranoside), for 20 h and the soluble overexpressed protein was affinity
purified on glutathione agarose (Sigma, St. Louis, MO, USA).
4.2. Plant Material and Extraction
4.2.1. Method of Preparation
Accelerated solvent extraction (ASE®) was used to generate macroalgal extracts using the Dionex
PLE system (ASE 200, Dionex, ThermoFisher Scientifics). Briefly, 2 g of each freeze-dried, de-fatted,
and powdered macroalga sample was mixed with 4 g of silica (Merck grades, 60 A, Sigma Aldrich,
Dublin, Ireland). Silica was used as an inert dispersant and the sample plus silica mixture was then
packed into 22-mL extraction cells. The automated extraction method used was 70% acetone in water
and a pressure and temperature of 50 ◦C, 1500 psi, respectively. The extraction time consisted of four
cycles of 5 min. Samples were dried using a rota-evaporator at 37 ◦C and subsequently freeze-dried to
remove water. Hexane was used to de-fat samples as previously described [41].
4.2.2. Species Name
3-Fucus distichus (Newfoundland origin); 4-Fucus vesiculosus (Linnaeus) ISCG 0223; 6-Cytoseira
tamariscofolia ISCG0283; 7-Cytoseira nodacaulis ISCG0070; 11-Alaria esculenta (Newfoundland origin);
Location of Harvest and Time: 3-Fucus distichus (Newfoundland origin) supplied by Oceans Ltd.
(St. John’s, NL, Canada) April 2010; 4-Fucus vesiculosus (Linnaeus) ISCG0223, Golf Course, Galway,
8 June 2011; 6-Cytoseira tamariscofolia ISCG0283, Finnavara, Co. Clare, 28 September 2011; 7-Cytoseira
nodacaulis ISCG0070, Finnavara, Co. Clare, 30 March 2010; 11-Alaria esculenta (Newfoundland origin)
kindly supplied by Dr. Anne Mathieu, Oceans Ltd., St. John’s Newfoundland. It was supplied in a
freeze-dried format. All seaweeds (Irish) were rinsed and subsequently freeze-dried prior to processing
and stored at −80 ◦C.
4.3. SIRT6 Deacetylation Assay
Solutions of macroalgal extracts at 0.5 and 1 mg/mL concentrations were prepared in DMSO.
In this study, 0.6 µL of this solution and DMSO (control) were incubated for 30 min in the presence
of 3 µg/well of SIRT6, 40 µM H3K9Ac, and 500 µM NAD+ in Tris Buffer (25 mM, pH 8.0) at 37 ◦C.
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Additional controls were carried out in the absence/presence of SIRT6, with or without NAD+ and
with and without fucoidan. During the reaction, the final solvent concentration of all samples was
1% DMSO. The samples were terminated by adding 6 uL cold 10% formic acid and subsequently
centrifuging for 15 min at 13.4 rpm. Dose-response effects (0.05 mg/mL to 1 mg/mL) were carried out
for sub-fraction F1 from F. distichus and commercial fucoidan from F. vesiculosus.
4.4. HPLC Analysis
The chromatographic separation of H3K9 and acetylated H3K9 was achieved on a Zorbax Eclipse
XDB-C18 column (4.6 mm × 50 mm, 1.8 µm; Agilent Technologies, Santa Clara, CA, USA) at room
temperature using a Shimadzu prominence system (Shimadzu Technology, Kyoto, Japan) consisting
of a CBM-20A, LC-20 AB binary pumps, an SIL-20AC-HT auto-sampler, and a DGU-20A3 degassing
unit. The mobile phase consisted of water with 0.02% formic acid (elute A) and acetonitrile with 0.02%
formic acid (elute B). The gradient eluent at a flow rate of 0.9 mL/min was programmed as follows:
0–2.0 min, 0% B; 2.0–10 min, 0–8% B; 10–10.10 min, 8–80% B; 10.10–12 min, 80%; 12–15 min 80–0% B;
15 min, 0% B. The total run time was 15 min and the injection volume per sample was 20 µL. The
HPLC system was coupled to a 5500 QTRAP from Applied Biosystems/MDS Sciex equipped with
Turbo V electrospray ionization source (TIS)® (Applied Biosystems, Foster City, CA, USA). The data
were acquired and analyzed using Analyst version 1.5.1 (Applied Biosystems). Positive electrospray
ionization data were acquired using multiple reactions monitoring (MRM). The TIS instrumental
source settings for temperature, curtain gas, ion source gas 1 (nebulizer), ion source gas 2 (turbo ion
spray), entrance potential, and ion spray voltage were 550 ◦C, 20 psi, 60 psi, 50 psi, 10 V, and 5500 V,
respectively. The TIS compound parameter settings for de-clustering potential, collision energy, and
collision cell exit potential were 231, 45, and 12 V, respectively, for H3K9Ac; and were 36, 43, and 12 V,
respectively, for H3K9. The standards were characterized using the following MRM ion transitions:
H3K9Ac (m/z 766.339→760.690) and H3K9 (m/z 752.198→746.717).
4.5. HPLC Fingerprint
The chromatographic separation of F. distichus was achieved on a Zorbax Eclipse XDB-C18 column
(4.6 mm × 50 mm, 1.8 µm; Agilent Technologies, Santa Clara, CA, USA) at room temperature using a
Shimadzu prominence system (Shimadzu Technology, Kyoto, Japan) consisting of a CBM-20A, LC-20
AB binary pumps, an SIL-20AC-HT auto-sampler, and a DGU-20A3 degassing unit. The mobile phase
consisted of water with 0.1% formic acid (elute A) and acetonitrile with 0.02% formic acid (elute B).
The gradient eluent at a flow rate of 0.6 mL/min was programmed as follows: 0 min, 0%B; 3.0 min,
0% B; 6.0 min, 83% B; 11.0 min, 83%; 11.1 min 0% B; 15 min, 0% B. The total run time was 15 min and
the injection volume per sample was 10 µl (7.5 mg/mL in 100 mM NaOH). Fractions were collected
(Figure 2) between 0.4–0.5 min (F1), 1.0–1.3 min (F2), 2.0–3.0 min (F3), 3.0–4.0 min (F4), 4.0–5.0 min
(F5), 5.1–5.3 min (F6), 5.4–5.5 min (F7), or 5.5–6.2 min (F8).
The HPLC system was coupled to a 5500 QTRAP from Applied Biosystems/MDS Sciex equipped
with Turbo V electrospray ionization source (TIS)® (Applied Biosystems, Foster City, CA, USA).
The data were acquired and analyzed using Analyst version 1.5.1 (Applied Biosystems). Negative
electrospray ionization data were acquired using enhanced MS (EMS) from 200 to 600 m/z. The TIS
instrumental source settings for temperature, curtain gas, ion source gas 1 (nebulizer), ion source gas 2
(turbo ion spray), entrance potential, and ion spray voltage were 500 ◦C, 20 psi, 50 psi, 60 psi, −10 V,
and −4500 V, respectively. The TIS compound parameter settings for de-clustering potential, collision
energy, and collision cell exit potential were −75, −35, and 12 V, respectively.
4.6. SemiPREP MS
The collection of the F1 sub-fraction of F. distichus was achieved on an Eclipse XDB-C8 column
(9.4 mm × 250 mm, 5 µm; Agilent Technologies, Santa Clara, CA, USA) at room temperature using
a Shimadzu prominence system (Shimadzu Technology, Kyoto, Japan) consisting of a CBM-20A,
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LC-20 ADXR binary pumps, an SIL-20AC-HT auto-sampler, and a DGU-20A3R degassing unit, PDA
(Photodiode array detector) SPD-M20A. The mobile phase consisted of water with 0.1% formic acid
(elute A) and acetonitrile with 0.02% formic acid (elute B). The gradient eluent at a flow rate of
0.9 mL/min was programmed as follows: 0 min, 0%B; 3.0 min, 0% B; 11.0 min, 83% B; 11.1 min, 0%;
15 min, 0% B. The total run time was 15 min and the injection volume per sample was 50 µL (10 mg/mL
in 100 mM NaOH). Fractions were collected (Figure 2) between 0.1–1.0 min (F1), 1.0–1.3 min (F2),
8.0–8.5 min (F3), 10.0–10.5 min (F4), or 11.0–11.4 min (F5).
The collected fractions were evaporated under nitrogen gas and dissolved two times with
methanol to remove impurities. Fractions were analyzed using HPLC–MS negative ionization mode
with a scan range of m/z 150–600.
4.7. H3K9 Western Blot Method
Fucoidan stock solution (10 mg/mL) was prepared and serially diluted in 25 mM Tris-HCl,
pH 8.0. Subsequently, 1 µL of fucoidan solution or buffer control were incubated in 20 µL reaction
for 30 min in the presence of 1 µg of a purified recombinant GST-SIRT6, 2 µg purified chicken
core histones (Millipore, Billerica, MA, USA), and 500 µM NAD+ in 25 mM Tris-HCl, pH 8.0 at
37 ◦C. The reactions were stopped with Laemmli sample buffer and separated by SDS-PAGE using
4–15% gradient gels (Bio-Rad, Hercules, CA, USA) and transferred onto polyvinylidene difluoride
(PVDF) membranes. H3K9 acetylation was detected with rabbit anti-acetyl H3K9 antibody (Millipore)
followed by anti-rabbit HRP-conjugated secondary antibody. Membranes were stripped and re-probed
with rabbit anti-histone H3 antibody. Chemiluminescent signal detection and image acquisition
were done using SuperSignal West Femto Substrate (Thermo) and ChemiDoc XRS+ with Image Lab
software (Bio-Rad).
4.8. In Vitro Enzymatic Assays (SIRT1-SIRT3)
The Fluor de Lys fluorescence assays were based on the method described in the BioMol product
sheet (Enzo Life Sciences, Ann Arbor, MI, USA) using the BioMol KI177 substrate for SIRT1 and
the KI179 substrate for SIRT2 and SIRT3. GST-SIRT1 and GST-SIRT2 were produced as described
previously [42,43]. His-SIRT3 (BML-SE270) was purchased from Enzo Life Sciences. DMSO (D2650),
SIRT assay buffer (HDAC assay buffer, KI143, supplemented with 1 mg/mL BSA, A3803), and NAD+
(N6522) were from Sigma. Fluor de Lys developer (KI176) and nicotinamide (BKI 283) were ordered
form BioMol.
Briefly, the reaction mixture including acetylated peptide substrate (0.7 Km: 58 µM for SIRT1 [44],
198 µM for SIRT2 [44], and 32 µM for SIRT3), NAD+ (0.9 Km: 558 µM for SIRT1, 547 µM for SIRT2,
and 2 mM for SIRT3), and DMSO/compounds in DMSO (2.5 µL in 50 µL total reaction volume) were
preincubated for 5 min at room temperature. The reaction was started by adding the enzyme following
incubation for 1 h at 37 ◦C. After that, the developer and nicotinamide (2 mM in HDAC assay buffer
giving total volume of 50 µL) were added and the incubation was continued for 45 min at 37 ◦C.
Fluorescence readings were obtained using a VictorTM 1420 Multilabel Counter (PerkinElmer Inc.,
Waltham, MA, USA) with an excitation wavelength of 355 nm and an emission of 460 nm, or EnVision
2104 Multilabel Reader (PerkinElmer, Waltham, MA, USA) with an excitation wavelength of 370 nm
and an emission of 460 nm.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/15/6/190/s1,
Figure S1: Fractionation (F1–F5) of F. distichus on the LC-MS/MS API-5500 and on the HPLC-DAD were collected
using an Eclipse XDB-C8 column (9.4 mm × 250 mm, 5 µm). Fractions were collected between 0.1–1.0 min (F1),
1.0–1.3 min (F2), 8.0–8.5 min (F3), 10.0–10.5 min (F4), 11.0–11.4 min (F5). Figure S2: HPLC-MS chromatograph of
subfraction F1 (10 µL). The flow rate was 0.6 mL/min a nd the injection volume was 10 µL of 7.5 mg/mL.
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